5.1 When NICE recommends a treatment as an option for use within the Cancer Drugs Fund, NHS England will make it available within the conditions of the managed access agreement. This means that, if a patient has Waldenstrom's macroglobulinaemia and the doctor responsible for their care thinks that ibrutinib is the right treatment, it should be available for use, in line with NICE's recommendations and the Cancer Drugs Fund criteria in the managed access agreement. Further information can be found in NHS England's Appraisal and Funding of Cancer Drugs from July 2016 (including the new Cancer Drugs Fund) – a new deal for patients, taxpayers and industry.
5.2 Ibrutinib has been recommended according to the conditions in the managed access agreement. As part of this, NHS England and Janssen have agreed a commercial access agreement that makes ibrutinib available to the NHS at a reduced cost. The financial terms of the agreement are commercial in confidence. Any enquiries from NHS organisations about the commercial access agreement should be directed to Janssen Customer Services on 0149 456 7400 or firstname.lastname@example.org.